Safety questions after the 2026 LiBBY dementia trial center on side effects seen in very late-stage illness. People with mild cognitive impairment can ask how those findings apply to earlier memory change.
LiBBY means Life's End Benefits of cannaBidiol and tetrahYdrocannabinol. The trial tested a fixed THC and CBD oil for agitation in hospice-eligible dementia, not in MCI. MCI means noticeable decline without loss of daily functioning.
Medical information disclaimer: This article is for general educational purposes only and does not provide medical advice, diagnosis, or treatment. Always consult a physician or other qualified health professional about symptoms, medications, tests, or treatment decisions.
Table of Contents
- What did researchers test?
- How much did agitation change?
- What safety results need questions?
- Why do results not transfer to MCI?
- Which questions help your next appointment?
What did researchers test?
LiBBY was a Phase 2 randomized, double-blind, placebo-controlled study in 120 hospice-eligible patients with dementia-related agitation. According to the Alzheimer's Association, care occurred across 10 United States home-visit sites trial details. Treated patients received purified oral oil with 2 mg THC plus 100 mg CBD twice daily.
According to NeurologyLive, this fixed T2:C100 formula was supplied for research, not dispensary cannabis formulation details. That design matters for safety questions. Dose, oil delivery, supervision, and end-of-life health status all shaped risks. A different product or setting changes the picture.
How much did agitation change?
Agitation means restlessness, verbal upset, or physical behaviors linked to dementia distress. The study used the Cohen-Mansfield Agitation Inventory, called CMAI, to score change over 12 weeks. According to the LiBBY Study site, treatment beat placebo by 8.23 points on CMAI at 12 weeks, with separation by week 2 study results.
Global improvement also favored treatment at weeks 2 and 12. According to Georgetown University School of Medicine, 83.9% versus 30.5% improved at week 2 and 87.2% versus 23.6% at week 12 on clinician global change Georgetown report. Those gains came from the supervised late-stage group only.
What safety results need questions?
Overall adverse events looked close between groups. Rates were 46.7% with THC and CBD versus 42.4% with placebo. Serious events pointed the other way. Serious adverse events were 23.3% with treatment versus 11.9% with placebo, mainly serious infections.
Deaths during 12 weeks were 13.1% versus 5.1%. Investigators reported no specific cause pattern and judged no serious event related to study drug. For MCI, the right question is not whether this proves harm at earlier stages. It is whether infection risk, frailty, drug interactions, falls, thinking changes, and driving safety could differ outside hospice care.
Why do results not transfer to MCI?
MCI and late-stage dementia differ in daily function, medical burden, supervision, and goals of care. The trial population was hospice-eligible with agitation, so its balance of benefit and risk fits that context. MCI care often focuses on diagnosis, reversible causes, sleep, mood, medicines, hearing, exercise, and planning.
A sedating or interacting product could affect work, driving, and other health conditions more directly. The LiBBY Study site states the findings apply only to that dose, oil system, and supervised end-of-life population. They do not support using over-the-counter or dispensary marijuana for agitation.
Which questions help your next appointment?
Bring your full medicine and supplement list, plus alcohol and sleep aids. Ask what applies to MCI rather than late-stage agitation. Ask your clinician to record the advice and next check date in your visit notes.
- Could THC or CBD interact with my medicines, blood pressure, sleep, mood, seizure threshold, or fall risk?
- Do I have infection, heart, lung, liver, or substance-use risks that need closer review?
- Are registered follow-up trials available for MCI, and what do they require?
- What non-drug steps fit my symptoms, diagnosis workup, safety plan, and follow-up schedule?
You Might Also Like
- AAIC 2026 LiBBY THC-CBD Agitation Trial: Questions People With Mild Cognitive Impairment Can Ask About the Research
- LiBBY Trial Findings for Late-Stage Dementia Agitation in 2026: Questions People With Mild Cognitive Impairment Can Ask About the Research
- The $100 Million PROTECT-Cog Alzheimer’s Study Announced in 2026: Questions People With Mild Cognitive Impairment Can Ask About the Research
